Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06516887 · ClinicalTrials.gov registry record · Phase 1
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
A Phase 1 study of Advanced Lung Adenocarcinoma, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06516887 is a Phase 1 study of Advanced Lung Adenocarcinoma that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 44 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06516887, a Phase 1 study of Advanced Lung Adenocarcinoma, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase Ib/II, open-label, single institution dose-escalation, safety, pharmacokinetics, pharmacodynamic and efficacy study.
Conditions Studied
Interventions
- DRUG pacritinib
- DRUG bemcentinib
Study Locations (1)
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-12-27 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06516887
The ClinicalTrials.gov registry entry for NCT06516887 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Lung Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which pacritinib is the first listed.
NCT06516887 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06516887 about?
NCT06516887 is a clinical study titled "Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma". This is a Phase Ib/II, open-label, single institution dose-escalation, safety, pharmacokinetics, pharmacodynamic and efficacy study.
What is the current status of trial NCT06516887?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2024-12-27. Estimated completion is 2027-09-01.
What conditions does trial NCT06516887 study?
This clinical trial studies the following conditions: Advanced Lung Adenocarcinoma.
What interventions are being tested in trial NCT06516887?
The interventions under investigation include: pacritinib (DRUG), bemcentinib (DRUG).
Who is sponsoring clinical trial NCT06516887?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06516887 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Lung Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.